


**2023
Institutional
Investors'
Conference**



TWSE: 4142

***Adimmune
Corporation***





Disclaimer

- Adimmune has not released any financial forecast. Business and financial information presented in this brief and during the Q&A session, should they concern business operation or industrial development, may differ materially from actual results. These discrepancies are due to such risks and uncertainties as market demand changes, price fluctuations, competitive behavior, global economic conditions, exchange rate fluctuations, supply chains etc., which are beyond Adimmune's control.
- The forward-looking statements contained in this brief are based on Adimmune's current expectations and speak only as of the date hereof. Adimmune assumes no obligation to update forward-looking statements as the result of new information or future events or developments.

FY2023 Q3 Consolidated Income Statement

Unit : NT\$ Thousands


Items	2023.Q3		2022.Q3	
	Reviewed	%	Reviewed	%
Sales Revenues	973,345		1,087,289	
Operating Costs	(488,399)		(531,705)	
Net operating margin	484,946	50%	555,584	51%
Operating expenses	(285,873)		(202,076)	
Selling expenses	(7,585)		(40,225)	
General and administrative expenses	(86,913)		(83,346)	
Research and development expenses	(83,707)		(78,505)	
Expected credit impairment gains(losses)	(107,668)		0	
Operating profit	199,073		353,508	
Non-operating income and expenses	30,219		52,925	
Profit before income tax	229,292	24%	406,433	37%
Income tax expense	0		0	
Net Profit	229,292		406,433	
Consolidated Net Income Attributed to Parent Company	263,707		419,517	
Consolidated Net Income Attributed to Subsidiaries	(34,415)		(13,084)	
EPS	0.63		0.98	

FY2023 Q3 Consolidated Income Statement


Unit : NT\$ Thousands

Items	2023.Q1-Q3 累計		2022.Q1-Q3 累計	
	Reviewed	%	Reviewed	%
Sales Revenues	1,225,604		1,667,022	
Operating Costs	(895,927)		(1,015,229)	
Net operating margin	329,677	27%	651,793	39%
Operating expenses	(668,624)		(586,535)	
Selling expenses	(70,159)		(139,667)	
General and administrative expenses	(241,510)		(218,740)	
Research and development expenses	(229,602)		(228,195)	
Expected credit impairment gains(losses)	(127,353)		67	
Operating profit	(338,947)		65,258	
Non-operating income and expenses	30,335		73,226	
Profit before income tax	(308,612)	-25%	138,484	8%
Income tax expense	0		0	
Net Profit	(308,612)		138,484	
Consolidated Net Income Attributed to Parent Company	(226,015)		230,209	
Consolidated Net Income Attributed to Subsidiaries	(82,597)		(91,725)	
EPS	(0.54)		0.54	

Revenues Generated from Global Market



Revenues Growth from CDMO Services



Corporate Development Plan



- **To continue exploring overseas markets for quadrivalent influenza vaccine**
 - Southern hemisphere market (Brazil), Middle East, and South Asia
- **Co-development and technology transfer of new products with strategic partners**
 - Multivalent enterovirus vaccine (Europe), 5-in-1 vaccine (Japan), dengue fever vaccine (Japan), zoster vaccine (Korea)
- **Strategic alliance**
 - Collaboration with WEGO Group for Southeast Asia market (tetanus vaccine, influenza vaccine)

Emergency Production during Pandemic Flu

In the case of the H7N9 vaccine, a Mock-up program for the parameters of commercial scale is established and supported by the CDC's APA program.

Tetanus Vaccine (TTA)

Platform optimization for international deployment


Research & Development Projects



Production Capacity Scaling-Up of EV71 Vaccine

- To start the commercialization of cell-based production of EV71 vaccine at the Tanzi campus.
- To increase 50L production capacity
- To scale up cell culture to 200L or higher (1000L)

**Collaboration with Chung
Hsing University to build
the Adimmune Biotech
R&D Center in Zhongxing
New Village.**



Q & A





THANK YOU

We look forward to working with you

OFFICE



No. 3, Sec. 1, Tanxing Rd.,
Tanzi Dist., Taichung City
427003 , Taiwan (R.O.C.)



+886-4-25381220



[https://www.adimmune.com.
tw/en](https://www.adimmune.com.tw/en)

TWSE: 4142